BETA-TALASEMIJA INTERMEDIJA I MINOR
Farmakološka indukcija sinteze fetalnog hemoglobina
hrvatski
Farmakološka indukcija sinteze fetalnog hemoglobina
/assets/ct/a63ae92c98/images/syn_placeholder_sqr.png

Beta-talasemija intermedija i minor

Farmakološka indukcija sinteze fetalnog hemoglobina

Terapija hidroksiurejom (hidroksiharbamid)

Hydroxyurea in thalassemia intermedia--a promising therapy. (otvara se novi prozor)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Izvor‎: Ann Hematol 2005;84(7):441-6.

Indeks‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (otvara se novi prozor)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (otvara se novi prozor)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Izvor‎: J Clin Pathol 2010;63(2):147-50.

Indeks‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (otvara se novi prozor)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (otvara se novi prozor)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Izvor‎: Eur J Haematol 2010;84(1):52-8.

Indeks‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (otvara se novi prozor)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (otvara se novi prozor)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Izvor‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indeks‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (otvara se novi prozor)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (otvara se novi prozor)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Izvor‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeks‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (otvara se novi prozor)

Rekombinantni eritropoetin (sam ili u kombinaciji s drugim sredstvima)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (otvara se novi prozor)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Izvor‎: Acta Haematol 2004;111(4):189-95.

Indeks‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (otvara se novi prozor)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (otvara se novi prozor)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Izvor‎: Blood Purif 2004;22(5):453-60.

Indeks‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (otvara se novi prozor)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (otvara se novi prozor)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Izvor‎: Br J Haematol 2011;154(2):281-4.

Indeks‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (otvara se novi prozor)